These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 9094648)

  • 21. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates.
    Scarlatti G; Albert J; Rossi P; Hodara V; Biraghi P; Muggiasca L; Fenyö EM
    J Infect Dis; 1993 Jul; 168(1):207-10. PubMed ID: 8515110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced capacity of antibodies from patients infected with human immunodeficiency virus type 1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses.
    Nyambi PN; Nkengasong J; Peeters M; Simon F; Eberle J; Janssens W; Fransen K; Willems B; Vereecken K; Heyndrickx L
    J Infect Dis; 1995 Nov; 172(5):1228-37. PubMed ID: 7594658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of primary isolate-like variants of simian-human immunodeficiency virus.
    Crawford JM; Earl PL; Moss B; Reimann KA; Wyand MS; Manson KH; Bilska M; Zhou JT; Pauza CD; Parren PW; Burton DR; Sodroski JG; Letvin NL; Montefiori DC
    J Virol; 1999 Dec; 73(12):10199-207. PubMed ID: 10559336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralizing antibodies in relation to antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus type I.
    Böttiger B; Ljunggren K; Karlsson A; Krohn K; Fenyö EM; Jondal M; Biberfeld G
    Clin Exp Immunol; 1988 Sep; 73(3):339-42. PubMed ID: 3208445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.
    Li M; Gao F; Mascola JR; Stamatatos L; Polonis VR; Koutsoukos M; Voss G; Goepfert P; Gilbert P; Greene KM; Bilska M; Kothe DL; Salazar-Gonzalez JF; Wei X; Decker JM; Hahn BH; Montefiori DC
    J Virol; 2005 Aug; 79(16):10108-25. PubMed ID: 16051804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of a primary isolate-like virus from simian and human immunodeficiency virus-infected macaque having broad neutralizing activity.
    Miyazaki Y; Kuwata T; Takehisa J; Hayami M
    AIDS Res Hum Retroviruses; 2002 Apr; 18(6):469-75. PubMed ID: 11958690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutralizing antibodies and viral characteristics in mother-to-child transmission of HIV-1.
    Scarlatti G; Leitner T; Hodara V; Halapi E; Rossi P; Albert J; Fenyö EM
    AIDS; 1993 Nov; 7 Suppl 2():S45-8. PubMed ID: 8161445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors.
    Zhang YJ; Fracasso C; Fiore JR; Björndal A; Angarano G; Gringeri A; Fenyö EM
    J Infect Dis; 1997 Nov; 176(5):1180-7. PubMed ID: 9359717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies.
    Hogervorst E; de Jong J; van Wijk A; Bakker M; Valk M; Nara P; Goudsmit J
    J Virol; 1995 Oct; 69(10):6342-51. PubMed ID: 7666535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.
    Hraber P; Rademeyer C; Williamson C; Seaman MS; Gottardo R; Tang H; Greene K; Gao H; LaBranche C; Mascola JR; Morris L; Montefiori DC; Korber B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.
    Stamatos NM; Mascola JR; Kalyanaraman VS; Louder MK; Frampton LM; Birx DL; VanCott TC
    J Virol; 1998 Dec; 72(12):9656-67. PubMed ID: 9811699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors.
    Montefiori DC; Pantaleo G; Fink LM; Zhou JT; Zhou JY; Bilska M; Miralles GD; Fauci AS
    J Infect Dis; 1996 Jan; 173(1):60-7. PubMed ID: 8537683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spectrum of HIV-1 neutralizing antibodies in a cohort of homosexual men: results of a 6 year prospective study.
    Robert-Guroff M; Goedert JJ; Naugle CJ; Jennings AM; Blattner WA; Gallo RC
    AIDS Res Hum Retroviruses; 1988 Oct; 4(5):343-50. PubMed ID: 3196490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multivariate analysis of human immunodeficiency virus type 1 neutralization data.
    Nyambi PN; Nkengasong J; Lewi P; Andries K; Janssens W; Fransen K; Heyndrickx L; Piot P; van der Groen G
    J Virol; 1996 Sep; 70(9):6235-43. PubMed ID: 8709250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection.
    Bunnik EM; Pisas L; van Nuenen AC; Schuitemaker H
    J Virol; 2008 Aug; 82(16):7932-41. PubMed ID: 18524815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates.
    Robert-Guroff M; Aldrich K; Muldoon R; Stern TL; Bansal GP; Matthews TJ; Markham PD; Gallo RC; Franchini G
    J Virol; 1992 Jun; 66(6):3602-8. PubMed ID: 1374810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection.
    Zhang PF; Chen X; Fu DW; Margolick JB; Quinnan GV
    J Virol; 1999 Jun; 73(6):5225-30. PubMed ID: 10233993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus.
    Wrin T; Crawford L; Sawyer L; Weber P; Sheppard HW; Hanson CV
    J Acquir Immune Defic Syndr (1988); 1994 Mar; 7(3):211-9. PubMed ID: 8106963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants.
    Dickover R; Garratty E; Yusim K; Miller C; Korber B; Bryson Y
    J Virol; 2006 Jul; 80(13):6525-33. PubMed ID: 16775339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses.
    Nara PL; Robey WG; Arthur LO; Asher DM; Wolff AV; Gibbs CJ; Gajdusek DC; Fischinger PJ
    J Virol; 1987 Oct; 61(10):3173-80. PubMed ID: 2442411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.